Clinical biomarker-based biological ageing and future risk of neurological disorders in the UK Biobank

被引:6
|
作者
Mak, Jonathan K. L. [1 ]
McMurran, Christopher E. [1 ,2 ]
Hagg, Sara [1 ]
机构
[1] Karolinska Inst, Dept Med Epidemiol & Biostat, S-17177 Stockholm, Sweden
[2] Univ Cambridge, Dept Clin Neurosci, Cambridge, England
来源
关键词
STROKE; MOTOR NEURON DISEASE; PARKINSON'S DISEASE; VASCULAR DEMENTIA; ALZHEIMER'S DISEASE; AGE;
D O I
10.1136/jnnp-2023-331917
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Many common neurological disorders are associated with advancing chronological age, but their association with biological age (BA) remains poorly understood.Methods We studied 325 870 participants in the UK Biobank without a diagnosed neurological condition at baseline and generated three previously-described measures of BA based on 18 routinely measured clinical biomarkers (PhenoAge, Klemera-Doubal method age (KDMAge), homeostatic dysregulation age). Using survival models, we assessed the effect of advanced BA on incident neurological diagnoses, including all-cause and cause-specific dementia, ischaemic stroke, Parkinson's disease and motor neuron disease.Results During a mean follow-up of 9.0 years, there were 1397 incident cases of dementia and 2515 of ischaemic stroke, with smaller case numbers of other diagnoses. The strongest associations with a 1 SD in BA residual were seen for all-cause dementia (KDMAge HR=1.19, 95% CI=1.11 to 1.26), vascular dementia (1.41, 1.25 to 1.60) and ischaemic stroke (1.39, 1.34 to 1.46). Weaker associations were seen for Alzheimer's disease and motor neuron disease, while, in contrast, HRs for Parkinson's disease tended to be <1. Results were largely consistent after adjustment for disease-specific covariates including common cardiometabolic risk factors.Conclusions Advanced BA calculated from routine clinical biomarker results increases the risk of subsequent neurological diagnoses including all-cause dementia and ischaemic stroke.
引用
收藏
页码:481 / 484
页数:4
相关论文
共 50 条
  • [21] Clinical biomarker-based biological age predicts deaths in Brazilian adults: the ELSA-Brasil study
    Machado, Amanda Viana
    de Mello e Silva, Juliana Freitas
    Colosimo, Enrico Antonio
    Needham, Belinda L.
    Maluf, Chams Bicalho
    Giatti, Luana
    Camelo, Lidyane V.
    Barreto, Sandhi Maria
    GEROSCIENCE, 2024, 46 (06) : 6115 - 6126
  • [22] Validation of a biomarker-based mortality score for cardiogenic shock patients: Comparison with a clinical risk score
    Hynninen, Elina
    Tolppanen, Heli
    Rivas-Lasarte, Mercedes
    Tarvasmaeki, Tuukka
    Harjola, Veli-Pekka
    Deniau, Benjamin
    Hongisto, Mari
    Jankowska, Ewa A.
    Jurkko, Raija
    Jaentti, Toni
    Kataja, Anu
    Mebazaa, Alexandre
    Sabell, Tuija
    Sionis, Alessandro
    Lassus, Johan
    ESC HEART FAILURE, 2025,
  • [24] Biomarker-based risk assessment model in acute pulmonary embolism
    Kostrubiec, M.
    Pruszczyk, P.
    Bochowicz, A.
    Pacho, R.
    Szulc, M.
    Kaczynska, A.
    Styczynski, G.
    Kuch-Wocial, A.
    EUROPEAN HEART JOURNAL, 2005, 26 : 304 - 304
  • [25] Biomarker-based risk assessment model in acute pulmonary embolism
    Kostrubiec, M
    Pruszczyk, P
    Bochowicz, A
    Pacho, R
    Szulc, M
    Kaczynska, A
    Styczynski, G
    Kuch-Wocial, A
    Abramczyk, P
    Bartoszewicz, Z
    Berent, H
    Kuczynska, K
    EUROPEAN HEART JOURNAL, 2005, 26 (20) : 2166 - 2172
  • [26] Biomarker-based staging of Alzheimer disease: rationale and clinical applications
    Therriault, Joseph
    Schindler, Suzanne E.
    Salvado, Gemma
    Pascoal, Tharick A.
    Benedet, Andrea Lessa
    Ashton, Nicholas J.
    Karikari, Thomas K.
    Apostolova, Liana
    Murray, Melissa E.
    Verberk, Inge
    Vogel, Jacob W.
    La Joie, Renaud
    Gauthier, Serge
    Teunissen, Charlotte
    Rabinovici, Gil D.
    Zetterberg, Henrik
    Bateman, Randall J.
    Scheltens, Philip
    Blennow, Kaj
    Sperling, Reisa
    Hansson, Oskar
    Jack Jr, Clifford R.
    Rosa-Neto, Pedro
    NATURE REVIEWS NEUROLOGY, 2024, 20 (04) : 232 - 244
  • [27] Biomarker-based staging of Alzheimer disease: rationale and clinical applications
    Joseph Therriault
    Suzanne E. Schindler
    Gemma Salvadó
    Tharick A. Pascoal
    Andréa Lessa Benedet
    Nicholas J. Ashton
    Thomas K. Karikari
    Liana Apostolova
    Melissa E. Murray
    Inge Verberk
    Jacob W. Vogel
    Renaud La Joie
    Serge Gauthier
    Charlotte Teunissen
    Gil D. Rabinovici
    Henrik Zetterberg
    Randall J. Bateman
    Philip Scheltens
    Kaj Blennow
    Reisa Sperling
    Oskar Hansson
    Clifford R. Jack
    Pedro Rosa-Neto
    Nature Reviews Neurology, 2024, 20 : 232 - 244
  • [28] Toward more informative biomarker-based clinical trials in glioblastoma
    Colman, Howard
    NEURO-ONCOLOGY, 2017, 19 (07) : 880 - 881
  • [29] Bayesian Baskets: A Novel Design for Biomarker-Based Clinical Trials
    Trippa, Lorenzo
    Alexander, Brian Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) : 681 - +
  • [30] Digital biomarker-based individualized prognosis for people at risk of dementia
    Buegler, Maximilian
    Harms, Robbert L.
    Balasa, Mircea
    Meier, Irene B.
    Exarchos, Themis
    Rai, Laura
    Boyle, Rory
    Tort, Adria
    Kozori, Maha
    Lazarou, Eutuxia
    Rampini, Michaela
    Cavaliere, Carlo
    Vlamos, Panagiotis
    Tsolaki, Magda
    Babiloni, Claudio
    Soricelli, Andrea
    Frisoni, Giovanni
    Sanchez-Valle, Raquel
    Whelan, Robert
    Merlo-Pich, Emilio
    Tarnanas, Ioannis
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2020, 12 (01)